Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yifeiyin
- Development stage
- Unknown
- Lead developer
- Tongde Hospital of Zhejiang Province
- Administration
- Oral
01
Overview
Yifeiyin is a Traditional Chinese Medicine (TCM) decoction developed by Tongde Hospital of Zhejiang Province for the treatment of non-small cell lung cancer (NSCLC). It is specifically utilized in patients with EGFR-sensitive mutations to delay the development of resistance to tyrosine kinase inhibitors (TKIs). The formulation is based on the TCM therapeutic principles of "spleen and kidney strengthening" and "detoxifying Sanjie." Clinical research, including the trial ChiCTR2000033640, focuses on evaluating its clinical efficacy and its role in modulating immune mechanisms to improve outcomes in advanced (Stage IIIb-IV) NSCLC patients.
- Other names
- Yifei DecoctionYifei Yin
Beyond the preview
Go deeper on yifeiyin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yifeiyin.